Sigurdsson A
Department of Medicine, Ostra Hospital Faculty of Medicine, Göteborg University, Sweden.
Blood Press Suppl. 1995;1:1-45.
Neurohormonal activation may provide a pathophysiological link between acute myocardial infarction and chronic congestive heart failure, and modulation of neurohormonal activity may be an important therapeutic target in these conditions. Plasma neurohormones were studied in 55 patients with acute myocardial infarction. Angiotensin II, noradrenaline and ANP were elevated in the early phase but tended to normalize during the first week in patients without signs of heart failure. In patients with heart failure angiotensin II and noradrenaline remained elevated for 1 month and ANP for 4-6 months. During head-up tilt, angiotensin II and noradrenaline increased most in patients with heart failure. In patients with a first myocardial infarction there was a positive correlation between sustained neurohormonal activity and infarct size. Almost complete suppression of plasma ACE activity was achieved within 30 min in 48 patients treated with intravenous enalaprilat, initiated within 24 h from the onset of infarction. The drug was tolerated in dosages of 1.0-1.2 mg given over 1-2h. Patients with systolic blood pressure between 100 and 110 mmHg incurred a greater risk of hypotension than those with higher blood pressure at baseline. Tolerance was not worse among patients treated with intravenous diuretics, metoprolol or nitroglycerin. A total of 98 patients were randomized to treatment with enalapril or placebo, initiated within 24 h from onset of infarction and continued for 4-6 months. During treatment there were no significant differences in plasma levels of angiotensin II, aldosterone, ANP or catecholamines between groups. Echocardiographic recordings were performed in 28 patients. Among patients on placebo there was a positive correlation between plasma levels of noradrenaline at days 5-7 and the increase in left ventricular volumes during the study period, and an inverse correlation between plasma aldosterone at days 5-7 and the increase in left ventricular ejection fraction during the study. No such correlation was found among patients on enalapril. ANP levels at 1 month correlated inversely with the left ventricular ejection fraction at the same time. Plasma neurohormones were measured in 223 patients with mild or moderately severe chronic heart failure, randomized to treatment with ramipril or placebo for 3 months. There was wide variation in hormone levels. Noradrenaline and aldosterone correlated inversely with exercise duration at baseline. Noradrenaline correlated positively with the degree of symptoms. Aldosterone and ANP were reduced with ramipril compared with placebo. Noradrenaline was reduced among patients with baseline levels in the highest tertile. Plasma hormones were also measured at peak exercise in 54 patients. Hormonal levels at rest correlated strongly with those at peak exercise.(ABSTRACT TRUNCATED AT 400 WORDS)
神经激素激活可能在急性心肌梗死和慢性充血性心力衰竭之间提供一种病理生理联系,而调节神经激素活性可能是这些疾病中的一个重要治疗靶点。对55例急性心肌梗死患者的血浆神经激素进行了研究。在无心力衰竭体征的患者中,血管紧张素II、去甲肾上腺素和心钠素在早期升高,但在第一周内趋于正常。在心力衰竭患者中,血管紧张素II和去甲肾上腺素持续升高1个月,心钠素持续升高4 - 6个月。在头高位倾斜时,心力衰竭患者的血管紧张素II和去甲肾上腺素升高最为明显。在首次发生心肌梗死的患者中,持续的神经激素活性与梗死面积呈正相关。48例在梗死发作后24小时内开始静脉注射依那普利拉治疗的患者,在30分钟内血浆ACE活性几乎完全被抑制。药物剂量为1.0 - 1.2mg,在1 - 2小时内给药,患者耐受性良好。收缩压在100至110mmHg之间的患者比基线血压较高的患者发生低血压的风险更大。接受静脉利尿剂、美托洛尔或硝酸甘油治疗的患者耐受性并不更差。共有98例患者被随机分为依那普利或安慰剂治疗组,在梗死发作后24小时内开始治疗,并持续4 - 6个月。治疗期间,两组间血管紧张素II、醛固酮、心钠素或儿茶酚胺的血浆水平无显著差异。对28例患者进行了超声心动图记录。在接受安慰剂治疗的患者中,第5 - 7天血浆去甲肾上腺素水平与研究期间左心室容积增加呈正相关,第5 - 7天血浆醛固酮水平与研究期间左心室射血分数增加呈负相关。在接受依那普利治疗的患者中未发现此类相关性。1个月时的心钠素水平与同一时间的左心室射血分数呈负相关。对223例轻度或中度重度慢性心力衰竭患者的血浆神经激素进行了测量,这些患者被随机分为雷米普利或安慰剂治疗组,治疗3个月。激素水平存在广泛差异。去甲肾上腺素和醛固酮与基线运动持续时间呈负相关。去甲肾上腺素与症状程度呈正相关。与安慰剂相比,雷米普利使醛固酮和心钠素降低。基线水平处于最高三分位数的患者中去甲肾上腺素降低。还对54例患者运动峰值时的血浆激素进行了测量。静息时的激素水平与运动峰值时的激素水平密切相关。(摘要截取自400字)